Bispecific antibody drug conjugate is a cutting-edge technology in the field of antibody drug development in recent years. It combines the targeting capability of bispecific antibodies (BsAb) with the potent cytotoxicity of antibody-drug conjugates (ADC), emerging as a new direction for precision-targeted therapy. BsADCs can not only recognize and bind two different antigens but also selectively kill tumor or diseased cells by delivering cytotoxic drugs. This enhances therapeutic specificity and efficacy while minimizing damage to healthy cells. BOC Sciences is dedicated to providing professional BsADC product development and custom services, offering a one-stop solution covering antibody engineering design, drug conjugation, functional validation, and quality control. Whether for basic research, drug development, or preclinical studies, we deliver safe, efficient, and reproducible services to our clients.
Bispecific antibody is an engineered antibody that can bind to two specific epitopes or target proteins at the same time. It has the ability to bind two different epitopes at the same time and can play some special biological functions. For example, effector cells can be directly targeted to tumor cells to enhance their cytotoxicity, improve antibody selectivity and functionality, costimulate or inhibit receptors, avoid immune evasion mechanisms, and improve therapeutic effects. BsAb also reduces the cost of drug development and clinical trials compared with combined treatment with two monoclonal antibody drugs. BsADCs have a novel dual-epitope/dual-target binding mode, which can not only expand the scope of drug treatment and improve tumor selectivity, but also significantly enhance the internalization effect of the drug. It is an emerging strategy for the development of a new generation of ADCs drugs. Currently, ten BsADCs have entered clinical trials. BsADCs have the following advantages:
BOC Sciences focuses on providing high-quality, customizable bispecific antibody conjugation services to research institutions and biopharmaceutical companies worldwide. With advanced antibody engineering technologies, professional drug conjugation platforms, and extensive R&D experience, we offer a one-stop solution from antibody design and drug conjugation to functional validation and quality control. Whether for early-stage research, preclinical studies, or customized requirements, our team delivers scientifically rigorous, efficient, and reproducible services to help clients accelerate project progress and achieve their R&D goals.
Supports IgG-like, BiTE, CrossMab, and other bispecific antibody formats. Combines complex target and multi-antigen requirements, offering personalized design solutions to ensure BsAb functionality and stability meet R&D and preclinical standards.
Integrates chemical, enzymatic, and site-specific conjugation strategies to produce highly homogeneous BsADC products, control DAR, optimize drug release timing, and improve therapeutic selectivity and efficacy stability.
Utilizes advanced purification technologies to obtain high-purity antibodies, combined with HPLC, mass spectrometry, and SDS-PAGE for systematic analysis of conjugation efficiency, structural integrity, and functional activity, ensuring each batch meets high scientific and development standards.
Experienced biochemistry and antibody drug development experts participate throughout the project, providing scientific guidance and optimization from antibody design and conjugation processes to functional validation, ensuring an efficient, controllable, and reliable R&D workflow.
Offers small-scale research samples or large-scale production support according to research stage and project needs. Develops personalized R&D plans based on client experimental protocols and special requirements, enabling rapid achievement of project objectives.
Equipped with state-of-the-art laboratories and conjugation platforms, combined with a complete R&D workflow—from antibody construction and drug conjugation to quality analysis and report delivery—shortening project cycles, ensuring high product consistency, and enhancing client R&D efficiency.
Engage in detailed discussions with clients to clarify target selection, drug type, conjugation strategy, and functional requirements. Fully understand research objectives and project goals to provide scientific guidance for antibody design and conjugation plans, ensuring the service process is efficient and accurate from the start.
Design suitable bispecific antibodies (BsAb) based on client needs. Optimize antibody structures to ensure dual-target binding capability and stability, laying the foundation for subsequent drug conjugation and functional validation, and ensuring excellent BsADC performance in targeted delivery.
Select chemical, enzymatic, or site-specific conjugation strategies according to research objectives and product requirements. Optimize conjugation efficiency and DAR to ensure precise delivery and functional activity of drugs to target cells while maintaining antibody structure and dual-target activity.
Conduct comprehensive functional testing of conjugated BsADCs, including dual-target binding, in vitro cytotoxicity evaluation, and stability testing, ensuring consistent performance under various conditions and providing reliable data for further R&D or preclinical studies.
Provide complete quality analysis reports, including conjugation efficiency, DAR, purity, stability, and functional validation results. Systematically summarize product performance using experimental data to support client R&D decisions and project advancement.
Optimize antibody design, conjugation processes, and drug combinations based on client feedback and experimental results. Continuously enhance BsADC performance to ensure the final product meets specific research or preclinical requirements, delivering high-quality, reproducible results.
Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time. This allows them to target two different molecules or cells simultaneously, thereby enhancing the therapeutic effect. Bispecific antibodies are being developed for a variety of applications, including cancer treatment, autoimmune diseases, and infectious diseases. They can redirect immune cells to attack specific targets, block two different signaling pathways, or deliver drugs to specific locations in the body.
Monoclonal antibodies are antibodies produced by identical immune cells that are clones of a unique parent cell. They are specific for a single antigen and bind to a single target on a cell or molecule. Bispecific antibodies are antibodies designed to bind to two different antigens simultaneously. This allows them to target two different molecules or cells simultaneously, which can be used to direct immune cells to attack specific targets or block two different pathways simultaneously.
Bispecific antibody conjugation (BsADC) is a technology that links a bispecific antibody (BsAb) to a cytotoxic drug, combining dual-targeting specificity with potent cell-killing capability. This approach enhances therapeutic selectivity, minimizes off-target effects, and is widely applied in cancer and immune-related research for precise drug delivery.
BOC Sciences offers a comprehensive BsADC workflow, including antibody design, drug selection, and site-specific conjugation. Our platform integrates chemical and enzymatic methods to control DAR, ensuring high-quality, functional conjugates. We also provide extensive functional validation and analytical characterization to guarantee reproducibility and reliability.
We support a variety of cytotoxic payloads, including microtubule inhibitors and DNA-damaging agents such as MMAE, DM1, and SN-38. Our team optimizes solubility, stability, and immunogenicity, selecting payloads tailored to your target cell type and research needs, ensuring effective delivery and enhanced BsADC therapeutic potential.
BOC Sciences offers chemical, enzymatic, and site-specific conjugation techniques. Chemical and enzymatic methods provide flexibility and efficiency, while site-specific approaches deliver highly uniform BsADC with controlled DAR. These strategies maximize payload delivery and maintain the antibody’s dual-targeting function, improving overall therapeutic performance.
BsADC products undergo comprehensive functional evaluation, including dual-target binding assays, in vitro cytotoxicity tests, and stability assessments. These analyses confirm that the conjugate retains high binding affinity, potent cell-killing activity, and structural integrity, ensuring reliability for downstream preclinical studies and research applications.
Yes, we provide fully customized BsADC services tailored to your research needs. This includes antibody design optimization, drug selection, conjugation strategy, and functional validation. We support projects at all scales, from small experimental batches to larger preclinical development, ensuring consistent quality and reproducibility.
Background
A biopharmaceutical R&D team from Germany was developing a bispecific antibody-drug conjugate (BsADC) targeting HER2 and EGFR to enhance selective killing of breast cancer cells. The project faced challenges including ensuring uniform DAR, maintaining dual-target binding activity, and meeting strict in vitro functional validation requirements.
How BOC Sciences Helped
BOC Sciences provided comprehensive, customized services covering antibody design optimization, drug selection, site-specific conjugation, and functional validation. The team worked closely with the client to design an antibody structure for the HER2/EGFR dual targets and selected MMAE as the cytotoxic payload for precise conjugation. This ensured high homogeneity, controllable DAR, and scientific guidance to support smooth project progress.
Implementation
Results
Browse BOC Sciences' publications to explore articles from research teams worldwide, showcasing the scientific contributions of our products and services in cutting-edge drug development.
"BOC Sciences delivered high-quality antibody-drug conjugates on a tight schedule. Their team provided clear guidance on conjugation strategies and ensured consistent product quality. Their expertise and responsiveness made the entire process smooth and reliable."
— Dr. Olivia Bennett, Biologics Scientist (United Kingdom)
"Our project required precise control over drug-to-antibody ratio for a complex ADC. BOC Sciences provided tailored solutions, thorough analytical data, and excellent technical support. Their professionalism and efficiency exceeded our expectations."
— Mr. Daniel Müller, Senior Research Associate (Germany)
"Working with BOC Sciences was seamless. They guided us through the selection of conjugation sites and ensured our antibody conjugates were stable and reproducible. The team's scientific knowledge and timely communication were invaluable for our research."
— Ms. Emily Roberts, Immunology Research Scientist (United States)
"We needed high-purity antibody conjugates for preclinical studies under tight deadlines. BOC Sciences delivered precise, well-characterized products along with comprehensive documentation. Their proactive support and technical expertise made them a trusted partner."
— Dr. François Leclerc, Translational Research Scientist (France)
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
Contact our experts today for pricing and comprehensive details on our ADC offerings.
